Skip to main content
. Author manuscript; available in PMC: 2026 Sep 19.
Published in final edited form as: Int J Tuberc Lung Dis. 2025 Oct 31;29(11):495–500. doi: 10.5588/ijtld.24.0637

Table 2.

Pharmacokinetic measurements of bedaquiline in 50 participants treated with bedaquiline for MDR-TB.

HIV-negative, n = 32 median (IQR) HIV-positive, n = 18 median (IQR) Geometric mean ratio (90% CI)
AUC0–22, mg·h/L 21.0 (16.1–30.7) 16.4 (12.9–20.0) 0.76 (0.61–0.94)
Cmax, mg/L 1.32 (1.00–2.14) 1.30 (0.97–1.46) 1.06 (0.94–1.20)
Tmax, h 6 (6–6) 6 (6–6) —
T1/2, h 16.4 (12.5–24.5); n = 31 14.5 (11.9–19.6); n = 18 —

Median with interquartile range is shown in brackets, where appropriate.

CI = confidence interval; IQR = interquartile range; MDR-TB = multidrug-resistant TB.